Ethical considerations in biomedical HIV prevention trials
Well into the third decade of the HIV epidemic, there remains no effective HIV preventive vaccine, microbicide, product or drug to reduce the risk of HIV acquisition. As the numbers of those infected by HIV and dying from AIDS continue to increase, the need for such biomedical HIV preventive interventions becomes ever more urgent. Several such products are at various stages of development, including some currently in phase III efficacy trials. The successful development of effective HIV preventive interventions requires that many different candidates be studied simultaneously in different populations around the world.
Related feature storiesWorld leaders unite towards ending the AIDS epidemic among adolescents
29 September 2014Leaving no one behind in the post-2015 development agenda: young marginalized people claim their space
26 September 2014Action on sexual and reproductive health and rights critical say leaders
24 September 2014